

Special Issue

MicroRNA and Cancer Immunology

Message from the Guest Editor

I am pleased to invite you to contribute to this Special Issue on "MicroRNA and Cancer Immunology" in *Cancers*. This issue seeks to illuminate the critical role of microRNAs (miRNAs) in the complex interplay within the tumor microenvironment and their impact on cancer progression. Recent research underscores the significance of miRNAs as modulators of immune cell function, tumor angiogenesis, and epithelial–mesenchymal transition (EMT). Their potential as biomarkers and therapeutic targets in cancer diagnosis, prognosis, and treatment highlights the importance of this burgeoning field. This Special Issue aims to collate and disseminate cutting-edge research and reviews exploring the multifaceted roles of miRNAs in cancer immunology. Our goal is to provide a comprehensive overview of current advances and encourage discussions that may shape future research directions in this vital area. In this Special Issue, original research articles and reviews are welcome. We look forward to receiving your contributions and fostering a rich dialogue in this dynamic and vital field of cancer research.

Guest Editor

Dr. Behzad Mansoori

Cellular and Molecular Oncogenesis Program, The Wistar Institute, Philadelphia, PA 19104, USA

Deadline for manuscript submissions

closed (15 September 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/193155

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)